

## H.I.G. Capital Acquires Majority Stake in Navitas Life Sciences to Accelerate CRO Growth



The global drug development market is expected to exceed \$70 billion in value by 2025, with more than half of the market's value driven by CROs. As demand for precision medicine continues to grow, so, too has demand for specialized capabilities to support and accelerate pharmaceutical and biotechnology development.

A technology-enabled specialty research organization, Navitas Life Sciences provides functional services and specialized technology such as pharmacovigilance technologies and life sciences data analytics for clients around the world. The company's strong fundamentals

combined with high growth potential made it an attractive acquisition opportunity for H.I.G. Capital, whose global network and diverse experience across healthcare and life sciences makes them an ideal partner to support Navitas' continued growth as a global next generation CRO.

Crosstree helped H.I.G. assess Navitas Life Sciences' strategic growth opportunities and confirm their investment rationale and offer. The resulting acquisition gives H.I.G. a majority stake in a platform at the forefront of drug development innovation with multiple paths to value creation.

**Crosstree helps clients evaluate and develop growth strategies that maximize value for all stakeholders.**

## ABOUT H.I.G CAPITAL



H.I.G. Capital is a leading global alternative investment firm with \$45 billion of equity capital under management, with a focus on the small cap and mid cap segments of the market. The H.I.G. family of funds includes private equity, growth equity, real estate, debt/credit, lending and biohealth. H.I.G. Capital invests in companies throughout the U.S., Europe and Latin America and have offices in Miami, New York, Boston, Chicago, Dallas, Los Angeles, San Francisco and Atlanta in the U.S., and affiliate offices in London, Hamburg, Luxembourg, Madrid, Milan and Paris in Europe as well as Bogotá, Rio de Janeiro and São Paulo in Latin America.

## ABOUT NAVITAS LIFE SCIENCES



Navitas Life Sciences is a technology-backed global clinical research organization serving large blue-chip pharmaceutical and biotech clients across North America, Asia Pacific, and Latin America. Navitas helps clients address their drug development needs by bringing together the capabilities of a full-service CRO, a technology-led life sciences services provider across clinical, regulatory and safety, and a life sciences big data services and analytics provider.

## CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

## MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



**JASON LAYTON**

Director

[jason.layton@crosstreecapital.com](mailto:jason.layton@crosstreecapital.com)

813-578-7109